1
|
Tam CSL, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss B, Moreno C, Szafer‐Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Ghia P, Wierda WG. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL). Hematol Oncol 2021. [DOI: 10.1002/hon.32_2879] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- C. S. L Tam
- Peter MacCallum Cancer Center & St. Vincent's Hospital and the University of Melbourne Haematology and Disease Group, Melbourne VIC Australia
| | - J. N Allan
- Weill Cornell Medicine, Hematology/Oncology New York USA
| | - T Siddiqi
- City of Hope National Medical Center Hematology Duarte USA
| | - T. J Kipps
- UCSD Moores Cancer Center Chronic Lymphocytic Leukemia San Diego USA
| | - R Jacobs
- Levine Cancer Institute Hematology and Medical Oncology Charlotte USA
| | - S Opat
- Monash University, Clinical Haematology Clayton VIC Australia
| | - P. M Barr
- Wilmot Cancer Institute University of Rochester Medical Center Hematology/Oncology Rochester USA
| | - A Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Haematology Milan Italy
| | - L Trentin
- Hematology and Clinical Immunology Unit Department of Medicine University of Padova, Hematology Padova Italy
| | - R Bannerji
- Rutgers Cancer Institute of New Jersey Hematology/Oncology New Brunswick USA
| | - S Jackson
- Middlemore Hospital, Haematology Auckland New Zealand
| | - B Kuss
- Flinders University and Medical Centre Haemotology and Molecular Genetics, Bedford Park SA Australia
| | - C Moreno
- Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Hematology Barcelona Spain
| | - E Szafer‐Glusman
- Pharmacyclics LLC, an AbbVie Company, Translational Medicine Sunnyvale USA
| | - K Russell
- Pharmacyclics LLC, an AbbVie Company, Clinical Program Development Sunnyvale USA
| | - C Zhou
- Pharmacyclics LLC, an AbbVie Company, Biostatistics Sunnyvale USA
| | - J Ninomoto
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - J. P Dean
- Pharmacyclics LLC, an AbbVie Company, Oncology Sunnyvale USA
| | - P Ghia
- ivision of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele, Experimental Oncology Milan Italy
| | - W. G Wierda
- University of Texas MD Anderson Cancer Center Leukemia Houston USA
| |
Collapse
|